Inari Medical, Inc. (NASDAQ:NARI) Receives $68.00 Consensus PT from Analysts

Shares of Inari Medical, Inc. (NASDAQ:NARI) have been given an average rating of “Hold” by the fourteen brokerages that are currently covering the stock, MarketBeat reports. Twelve equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $68.00.

A number of research firms have recently weighed in on NARI. Baird R W cut Inari Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 7th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $80.00 target price (up previously from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Oppenheimer started coverage on Inari Medical in a research note on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 price target for the company. Robert W. Baird restated a “neutral” rating and set a $80.00 price objective (down from $81.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Finally, Piper Sandler increased their target price on shares of Inari Medical from $52.00 to $80.00 and gave the company a “neutral” rating in a research report on Tuesday, January 7th.

Insiders Place Their Bets

In other Inari Medical news, Director William Hoffman sold 200,000 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the sale, the director now owns 238,987 shares in the company, valued at approximately $14,451,543.89. The trade was a 45.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Mackenzie Financial Corp raised its position in Inari Medical by 59.7% during the fourth quarter. Mackenzie Financial Corp now owns 1,363,697 shares of the company’s stock valued at $69,617,000 after acquiring an additional 509,868 shares in the last quarter. PharVision Advisers LLC acquired a new stake in shares of Inari Medical during the 4th quarter worth approximately $207,000. Woodline Partners LP bought a new stake in Inari Medical in the 4th quarter valued at $36,394,000. Tema Etfs LLC acquired a new position in Inari Medical in the fourth quarter worth about $755,000. Finally, Snowden Capital Advisors LLC acquired a new stake in Inari Medical in the 4th quarter valued at $225,000. 90.98% of the stock is owned by institutional investors and hedge funds.

Inari Medical Price Performance

Shares of NASDAQ:NARI opened at $79.97 on Friday. The company’s 50-day moving average price is $79.84 and its 200 day moving average price is $60.81. The company has a market cap of $4.68 billion, a PE ratio of -59.24 and a beta of 1.02. Inari Medical has a fifty-two week low of $36.73 and a fifty-two week high of $79.99.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.